Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.
Matinas BioPharma Holdings, Inc. develops biopharmaceutical therapies using its lipid nanocrystal, or LNC, delivery technology. Company updates center on MAT2203, an oral formulation of amphotericin B for invasive fungal infections, along with broader LNC platform applications for intracellular delivery of small molecules and oligonucleotides.
Recurring MTNB news also covers operating and financial results, clinical and regulatory disclosures, governance changes, shareholder ownership activity, capital-structure matters, and NYSE American continued-listing compliance. The company’s announcements connect its drug-development work with board oversight, financing needs, and public-company requirements.
Matinas BioPharma (NYSE: MTNB) announced a conference call on August 10, 2021, at 8:00 a.m. ET to discuss Q2 2021 operational and financial results. The call can be accessed by dialing (877) 407-5976 or through the company's website. Matinas is focused on enhancing drug delivery through its lipid nanocrystal (LNC) technology, with key products in development, including MAT2203 for cryptococcal meningitis and MAT2501 for bacterial infections. The company aims to address significant challenges in intracellular drug delivery, showing promise in various therapeutic areas.
Matinas BioPharma (MTNB) has announced a virtual R&D Day on June 17, 2021, at 8:30 a.m. ET, highlighting its lipid nanocrystal (LNC) delivery platform and pipeline programs. Key leaders, including Professors David Boulware and Peter Pappas, will provide clinical insights. The company is developing products like MAT2203 for cryptococcal meningitis and MAT2501 for nontuberculous mycobacterial lung infections, backed by funding from the Cystic Fibrosis Foundation. LYPDISO™ shows promising results in triglyceride management against Vascepa. A live Q&A session will follow the presentations.
Matinas BioPharma Holdings, Inc. (MTNB) reports Q1 2021 results with significant progress in clinical studies. Patient enrollment in the EnACT study for MAT2203, targeting cryptococcal meningitis, is at 70%, with a DSMB evaluation expected in Q3 2021. MAT2501 advances to preclinical studies, aiming for a Phase 1 study by year-end. Financially, cash reserves stand at $60.7 million, aiding operations into 2024. A net loss of $5.2 million was reported, unchanged from Q1 2020, while R&D expenses decreased to $3.2 million. Management remains optimistic about future developments and partnerships.
Matinas BioPharma (MTNB) announced that CEO Jerome D. Jabbour will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 11:20 a.m. ET. The company will also host investor meetings during the event. A live webcast of the presentation will be available on the company's website, with a replay accessible for 90 days. Matinas focuses on improving drug delivery through its lipid nanocrystal (LNC) platform and is developing multiple product candidates, including MAT2203 and MAT2501 for serious infections.
Matinas BioPharma Holdings (MTNB) will host a conference call on May 10, 2021, at 8:00 a.m. ET to discuss its Q1 2021 operational and financial results. The call can be accessed by dialing (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll), and will also be available via live webcast on the company's website. Matinas focuses on lipid nanocrystal technology for drug delivery, with ongoing studies for MAT2203, MAT2501, and LYPDISO, aimed at treating serious infections and cardiovascular conditions. Investors should note the inherent risks and uncertainties in their forward-looking statements.
Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present an overview of the company at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 4:30 p.m. ET. The presentation will be available via live webcast on the company's investor relations page, with a replay accessible for 90 days. Matinas is focused on its innovative lipid nanocrystal delivery platform, developing products like MAT2203 for fungal infections and MAT2501 for bacterial infections, both in advanced clinical stages.
Matinas BioPharma Holdings (MTNB) reported its Q4 and full-year 2020 financial results, showing a net loss of $6.6 million for Q4 and a total of $23.2 million for the year, reflecting increased R&D expenses. The company is focused on its Lipid Nanocrystal (LNC) platform for intracellular drug delivery, with ongoing enrollment in the EnACT study of MAT2203 for cryptococcal meningitis. Significant partnerships are in progress, including collaboration with NIAID on remdesivir. Cash reserves stand at $58.7 million, expected to fund operations into 2024.
Matinas BioPharma (NYSE: MTNB) announced a conference call on March 29, 2021, at 8:00 a.m. ET, to discuss its Q4 and full-year 2020 financial results. The call can be accessed by dialing (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll). Matinas is focused on developing therapeutics for unmet medical needs, including LYPDISO for hypertriglyceridemia and MAT2203 for cryptococcal meningitis in HIV patients. The company aims to solve drug delivery challenges through its proprietary lipid nanocrystal platform and has received funding from the Cystic Fibrosis Foundation to support MAT2501.
Matinas BioPharma (MTNB) announced CEO Jerome D. Jabbour will present a company overview at the Barclays Global Healthcare Conference on March 9, 2021, at 4:45 p.m. ET. The presentation will include investor meetings and will be available via a live webcast on the company’s investor relations page. Matinas focuses on developing innovative therapeutics, including LYPDISO for hypertriglyceridemia, MAT2203 for fungal infections, and MAT2501 for bacterial infections. The company aims to improve drug delivery through its proprietary lipid nanocrystal platform.
Matinas BioPharma Holdings announced the topline results for its ENHANCE-IT study, comparing LYPDISO™ against Vascepa®. Key findings showed a 46% relative increase in EPA levels and a 39% reduction in triglycerides (TGs) versus Vascepa, although the latter did not meet statistical significance. However, LYPDISO™ demonstrated significant reductions in several lipid and inflammatory markers in the per-protocol population. The study involved 100 participants and aimed to assess cardiovascular risk reduction potential.